Market news

Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]

Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...

Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...

Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.

Precigen has seen its stock climb sharply in recent years, which naturally puts the focus on what investors are paying for each dollar of its sales. With the share price at US$7.87 at the last close, the open question is whether that level is adequately supported by the company’s current revenue base. Over the past 3 years the stock has returned about 4.6x, which puts a lot of weight on whether its sales profile can carry that kind of re-rating. For a business like Precigen, future outcomes...

PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.

Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.

Jeffrey B Kindler, Director, on August 26, 2026, sold 185,000 shares in Precigen (PGEN) for $1,376,4

Event driven interest in Precigen stock Fresh attention on Precigen (PGEN) follows commentary that new drug approvals and pipeline progress could support the Zacks Biomedical and Genetics industry, with Papzimeos highlighted for recurrent respiratory papillomatosis. Investors are weighing how Papzimeos commercial performance and Precigen's broader gene and cell therapy pipeline might relate to recent share price moves and the company’s current valuation profile. At a latest share price of...

Recent commentary on the Zacks Biomedical and Genetics industry highlighted Precigen’s past momentum, citing steady commercial performance from its sole marketed drug Papzimeos for recurrent respiratory papillomatosis and encouraging pipeline progress despite a challenging macro backdrop. The focus on Papzimeos as a single commercial pillar underscores both the company’s concentration risk and the importance of its broader development portfolio to diversify future revenue sources. We’ll now...

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

GERMANTOWN, MD / ACCESS Newswire / August 25, 2026 / For Germantown, MD-based Precigen Inc. (NASDAQ:PGEN), the second quarter marked a commercial inflection. PAPZIMEOS (zopapogene imadenovec-drba) generated $53.1 million in net product revenue-more than double the prior quarter-and helped the company achieve quarterly profitability.

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Precigen’s latest earnings matter for investors Precigen (PGEN) drew fresh attention after its second quarter 2026 earnings, where revenue reached US$54.98 million and net income came in at US$20.07 million, following the commercial launch of PAPZIMEOS. See our latest analysis for Precigen. Precigen’s latest earnings arrived alongside strong share price momentum, with a 30 day share price return of 28.95% and a 90 day share price return of 65.30%. The 1 year total shareholder return of...

Detailed price information for Precigen Inc (PGEN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Precigen Inc (PGEN-Q) from The Globe and Mail including charting and trades.

Precigen (NASDAQ:PGEN) reported a sharp increase in second-quarter revenue from its PAPZIMEOS launch, with the company reaching quarterly profitability less than a year after the therapy’s August 2025 FDA approval for adults with recurrent respiratory papillomatosis, or RRP. PAPZIMEOS revenue total

Precigen (PGEN) delivered earnings and revenue surprises of +350.00% and +97.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.

GERMANTOWN, Md. , July 21, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced...

Focused on gene and cellular therapies, this biotech firm reported a notable insider sale amid a year of rapid share price gains.